---
title: "iBio names endocrinologist Molly Carr as chief medical officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294812224.md"
description: "iBio has appointed endocrinologist Molly Carr as its new Chief Medical Officer. In this role, Carr will lead global clinical strategy, medical affairs, and regulatory efforts for the company's cardiometabolic pipeline. She previously served as Clinical Head at Eli Lilly’s Insulin and Glucagon Franchise, overseeing the Phase 3 efsitora program, and holds prior senior positions at GSK, CSL Behring, and Wyeth."
datetime: "2026-08-04T11:06:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294812224.md)
  - [en](https://longbridge.com/en/news/294812224.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294812224.md)
generator: "portal-rs"
---

# iBio names endocrinologist Molly Carr as chief medical officer

-   iBio named endocrinologist Molly Carr as chief medical officer to lead global clinical strategy, medical affairs, regulatory work for its cardiometabolic pipeline. \* Carr most recently served as clinical head, associate vice president of Eli Lilly’s Insulin and Glucagon Franchise, overseeing the Phase 3 efsitora program. \* Her prior roles included senior positions at GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University, the University of Washington. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802906) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md)
- [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [Analyst Warns of Significant Clinical and Regulatory Risks Facing Ibio Inc’s Drug Pipeline](https://longbridge.com/en/news/297478349.md)
- [iBio announces annual shareholder meeting](https://longbridge.com/en/news/298071487.md)
- [iBio CEO joins Wells Fargo Annual Healthcare Conference fireside chat](https://longbridge.com/en/news/297695352.md)
- [iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000](https://longbridge.com/en/news/297313027.md)
- [iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing](https://longbridge.com/en/news/297325770.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**